There is evidence that CMV may be transmitted by transfusion of white blood cells which harbor viruses. Frozen reconstituted RBC are virtually free of leukocytes. This prospective study randomly selects neonates requiring blood transfusions. Group A infants received frozen reconstituted RBC, Group B reqular blood with negative CMV titer and qroup C regular blood with positive CMV titers. Maternal, umbilical cord and donor's blood were tested for CMV complement fixation titers. Follow-up serologic studies were carried out at 8 and 18 weeks.Urine was cultured for CMV at birth and at the same follow-up schedule. Transfusion acquired infection is defined as seroconversion, a rising titer or a positive urine culture at 8 to 18 week follow-up period.
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The pneumcoccus is the pathogen recovered most often from blood cultures in our hospital. We identified 205 episodes of systemic pneumococcal infections in 201 children during a 34 mo. period. There were 54 infections in 1978 (10 months), 64 in 1979 and 87 in 1980. The frequency of infections was hiqhest in May and April (mean number of episodes/month 10.3 and 9.3 respectively) and was lowest in August and September (1.3 and 1.6). Children with pneumococcal infection ranged in age from 1 month to 14 years (mean age of 20 months). There were 126 boys and 75 girls. Seventy six percent of the children were black. Occult bacteremia (128 episodes) was the most frequently seen illness. There were 40 instances of pneumonia with bacteremia, 31 of meningitis, 4 of cellulitis and 2 of septic arthritis. Three children had recurrent infections: one with sickle cell anemia had three separate episodes caused by type 23F despite having received pneumococcal vaccine. Four children died: two had meningitis, one (asplenic child) had bacteremia and one (with myocarditis) had bacteremic pneumonia. One hundred thirty isolates were serotyped. During a 19 day period in 1982, 4 of 12 infants in an NICU room at the University of Illinois developed hyperbilirubinemia with or without thrombocytopenia, fever or respiratory distress. Each of the 4 infants was viruric with CMV. All 4 were premature (gestational ages 26-31 weeks), were at least 1 month old at onset of symptoms (range 36-79 days) and had received multiple transfusions of packed red blood cells (range 4-11 transfusions; 94-150 cc total volume). Although the mothers of all 4 infants had IgG to CMV, none had anti-CMV IgM; cervical cultures were obtained from 2 of the 4 mothers, and CMV was not recovered.
BamHl restriction-endonuclease analysis of all 4 CMV isolates showed identical banding patterns in the CMV's of 2 infants who had received blood from a common donor. The other 8 infants were followed for acquisition of CMV; none developed viruria. Of the 11 female health-care personnel in closest contact with the CMVinfected infants, 2 had anti-CMV IgG, but neither showed rises in titer or developed anti-CMV IgM. The other 9 remained seronegative 1 month following their exposure. Restriction-endonuclease analysis, used here in conjunction with conventional epidemiology indicates a low risk of CMV transmission from infected, tertiarycare NICU infants to other neonates or to health-care personnel.
ENHANCED IMMUNOGENICITY I N YOUNG INFANTS OF A NEW HAEMOPHILUS INFLUENZAE TYPE B(HIB) CAPSULAR POLYSAC-
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To enhance t h e immune response t o PRP i n young i n f a n t s , we emp l o y e d a conjugate vaccine whose s y n t h e s i s i s based upon t h e hapt e n -c a r r i e r p r i n c i p l e f o r i n d u c i n g T -c e l l immune responses. PRP was c o v a l e n t l y coupled t o D t o make t h e PRP-D c o n j u g a t e vaccine. To e v a l u a t e immunogenicity and s a f e t y i n t h e c r u c i a l age group <6months we e n r o l l e d 60 newborns i n t o a double b l i n d placebo(sa1-i n e ) c o n t r o l l e d t r i a l t o r e c e i v e PRP-D vaccine a t ages 2,4,and 6 mos. c o n c u r r e n t w i t h DTP. Shown i s t h e GMT anti-PRP AB conc. Imnune responses were observed a f t e r t h e 2nd dose and a l l respond a t e . i n d i v i dd e r s t h e n boosted a f t e r t h e 3 r d dose(avg.6fold). To u a l PRP-D resoonses a t 7 mos. were: <. 05, 0.4. 0.8, 3.3,.4.6 and 13.5ualml . ~r e l i m i n a r v ELISA d a t a suqqests t h e h i q h e s t responses w e r e ' i g~. There was nb d i f f e r e n c e i n -r e a c t i o n r a t e s ( l o c a 1 o r systemic) between PRP-D o r s a l i n e groups.
I n t h e p o p u l a t i o n o f young i n f a n t s a t g r e a t e s t HIB disease r i s k , PRP-D appears t o be s a f e and have enhanced immunogenicity. Presence o f an AB boost and IgG AB suggests a T -c e l l a m p l i f i c a ti o n o f t h e PRP immune response w i t h conjugate vaccines.
PASSIVE PROTECTION FOR HAEMOPHILUS INFLUENZAE TYPE B (HIB) DISEASE: ANTIBODY LEVELS I N INFANTS GIVEN HYPER-
' ' 15' T,4M,lNF GI ORIII TN. J o~l ,. Nard*. Donna Ambrosino.
----------. ----. Groups a t h i g h r i s k i n c l u d e : household c o n t a c t s daycare c e n t e r c o n t a c t s , Eskimo and I n d i a n i n f a n t s , s i c k l e c e l l and immunocompromised p a t i e n t s . HIG, prepared from pooled sera o f a d u l t s immunized w i t h PRP, c o n t a i n s a 10-20 f o l d i n c r e a s e i n anti-PRP AB ( 6 0 0~g / m l ) compared t o standard I.G.
To e v a l u a t e t h e s a f e t y and pharmacokinetics of HIG, we gave 2 doses t o 14 i n f a n t s a t 2 and 6 mos. o f age. The GMT anti-PRP AB l e v e l s measured by RIA(ng/ml) were: There was l i t t l e v a r i a b i l i t y i n dose response. Assuming a p r o t e c t i v e l e v e l o f 150ng/ml, t h e low dose and h i q h dose regimens would be expected t o p r o v i d e 3 mos. and 4 mos. p r o t e c t i o n , respec
